Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=24236454
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\24236454
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Curr+Mol+Med
2014 ; 14
(3
): 385-95
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Novel adjunctive therapies for the treatment of tuberculosis
#MMPMID24236454
Ordonez AA
; Maiga M
; Gupta S
; Weinstein EA
; Bishai WR
; Jain SK
Curr Mol Med
2014[Mar]; 14
(3
): 385-95
PMID24236454
show ga
Despite significant efforts to control tuberculosis (TB), the disease remains a
major global threat, with an estimated 8.6 million new cases and 1.3 million
deaths in 2012 alone. Significant treatment challenges include HIV co-infection,
the dramatic rise of multidrug-resistant TB and the vast reservoir of latently
infected individuals, who will develop active disease years after the initial
infection. The long duration of chemotherapy also remains a major barrier to
effective large scale treatment of TB. Significant advances are being made in the
development of shorter and effective TB drug regimens and there is growing
evidence that host-directed and "non-antimicrobial" pathogen-directed therapies,
could serve as novel approaches to enhance TB treatments. This review highlights
the rationale for using these therapies and summarizes some of the progress in
this field.